Investigation using an HER-2/neu transgenic mouse model of a newly developed MR contrast agent with the effect of an antitumor drug

• Published in: Journal of magnetic resonance imaging 2009-10, Vol.30 (4), p.907-910
• Main Authors: Sonoda, Akinaga, Nitta, Norihisa, Ohta, Shinich, Nitta-Seko, Ayumi, Murata, Satoshi, Jo, Jun-ichiro, Tabata, Yasuhiko, Takahashi, Masashi, Tani, Toru, Murata, Kiyoshi
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Cattle; cis diamminedichloroplatinum; Cisplatin - administration & dosage; Cisplatin - chemical synthesis; Cisplatin - pharmacology; Contrast Media - administration & dosage; Contrast Media - chemical synthesis; Contrast Media - pharmacology; Cross-Linking Reagents - administration & dosage; Cross-Linking Reagents - chemical synthesis; Cross-Linking Reagents - pharmacology; diethylenetriaminepentaacetic acid; Disease Models, Animal; Female; gadolinium; Gadolinium DTPA - administration & dosage; Gadolinium DTPA - analogs & derivatives; Gadolinium DTPA - chemical synthesis; Gadolinium DTPA - pharmacology; gelatin; Gelatin - administration & dosage; Gelatin - chemical synthesis; Gelatin - pharmacology; Genes, erbB-2; HER-2/neu transgenic mice; Magnetic Resonance Imaging - methods; Mammary Neoplasms, Experimental - diagnosis; Mammary Neoplasms, Experimental - drug therapy; Mice; Mice, Transgenic
• ISSN: 1053-1807; 1522-2586
• DOI: 10.1002/jmri.21911

Purpose To assess whether Gd‐DTPA‐Gel‐Cis, a conjugate of gadolinium (Gd), cis diamminedichloroplatinum (Cis), diethylenetriaminepentaacetic acid (DTPA)‐dianhydride, and bovine gelatin (Gel) can be used as an intravascular contrast agent at MRI and as an antitumor cell proliferation agent in vitro. Materials and Methods We injected Gd‐DTPA‐Gel‐Cis (200 mg/mL) into the caudal vein of female HER‐2/neu transgenic mice with spontaneous mammary tumors. The tumor signal intensity was measured with a 0.3 Tesla MRI scanner. HER‐2/neu‐expressing NT cells were treated with Gd‐DTPA‐Gel‐Cis (5 μM cisplatin, 200 mg/mL Gel), Cis alone (5 μM cisplatin), or Gel alone (200 mg/mL gelatin). Differences of P < 0.05 were considered to be statistically significant. Results On T1‐weighted MRI scans of mice injected with Gd‐DTPA‐Gel‐Cis we observed a 23% increase in signal intensity. The survival rates of cells exposed to Gd‐DTPA‐Gel‐Cis or Cis were 70.9% and 58.3%, respectively, of the survival rates observed after treatment with Gel alone. Gd‐DTPA‐Gel‐Cis showed significant toxicity (P < 0.05). Conclusion Gd‐DTPA‐Gel‐Cis shows promise for use as an MRI contrast medium and as an antitumor agent. J. Magn. Reson. Imaging 2009;30:907–910. © 2009 Wiley‐Liss, Inc.